Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer

September 26, 2018, South San Francisco, CA

Read More

Second Genome Certified as Great Place to Work®

July 31, 2018, South San Francisco, July 30, 2018

Read More

Second Genome Appoints Anupama S. Hoey as Chief Business Officer

July 23, 2018, South San Francisco, July 23, 2018

Read More

Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018

April 9, 2018, SOUTH SAN FRANCISCO, Calif.,

Read More

Second Genome Appoints Matthew W. McClure, M.D., as Chief Medical Officer

March 5, 2018, South San Francisco, CA March 5, 2018

Read More

Second Genome Strengthens R&D Program in Immuno-Oncology with Four Academic Collaborations

February 28, 2018, Feb. 28, 2018

Read More

Second Genome Advances Lead, Oral Small Molecule SGM-1019, Toward Clinical Investigation in NASH After Demonstrating Safety and Tolerability in Phase 1 Study

December 19, 2017, SOUTH SAN FRANCISCO, Calif., Dec 19, 2018

Read More

Second Genome Launches Study of the Relationship Between Microbiome and Central Nervous System in Autism Spectrum Disorders

October 3, 2017,

Fast-Track SBIR grant applied towards the development of a commercial platform for discovery and validation of key microbial metabolites linked to CNS disorders

Read More